|Podcasts|May 25, 2023

Emerging Potential: Changing Lives One Story, One Therapeutic at a Time

Author(s)Meg Rivers

The 2023 Emerging Pharma Leaders share with the Pharmaceutical Executive editors what makes a good leader, what has made them the proudest in their career, lessons they wish they had known when starting out, and more. (This is the audio-only Pharm Exec Podcast episode!)

Each year, Pharmaceutical Executive recognizes up-and-coming leaders who are vital to the future of the pharmaceutical and biotech industry in the Emerging Pharma Leaders (EPL) Awards. Nominations are judged by three members of the Editorial Advisory Board as well as a former EPL representative. This year, five winners were selected, all of whom had incredible journeys to share with the editorial team.

The Pharm Exec team would like to congratulate the 2023 Emerging Pharma Leaders:

  1. Natasha A. Hernday, chief business officer, Seagen
  2. Simon Holland, vice president, women's health commercial lead, Organon
  3. Justin To, chief operating officer, skeletal dysplasias and gene therapy, Bridge Bio
  4. Frank Watanabe, president and CEO, Arcutis Biotherapeutics
  5. Hanadie Yousef, PhD, co-founder and CEO, Juvena Therapeutics

In this episode of the Pharm Exec Podcast, Meg Rivers, managing editor, and the editorial team speak with the EPL winners, asking each about:

  • Their current role and responsibilities
  • What makes a good leader
  • What has made them the proudest in their career 
  • Lessons they wish they had known when starting out
  • What’s next for them in their career


Sponsor

APEX Awards


Watch the video version of this podcast


Read about the 2023 Emerging Pharma Leaders


About the Pharm Exec Podcast

The editors of Pharmaceutical Executive bring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.

Listen to this podcast on SoundCloud, Spotify, Google Podcasts, or Apple Podcasts.


Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.